Injectable insulin has been around since 1923, but oral insulin has proven elusive to date. Oramed Pharmaceuticals' successful Phase IIB trial for oral insulin has shown that it can be done. http://seekingalpha.com/article/3987206-oramed-now-first-show-evidence-insulin-can-taken-orally
http://www.dailymotion.com/video/x4jqi3z
Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race... http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/
https://marketexclusive.com/weekly-biotech-report-part-ii-oramed-pharmaceuticals-inc-nasdaqormp/2016/05/
http://www.reuters.com/article/us-oramed-insulin-idUSKCN0Y91F2
JERUSALEM, April 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place [...]
Top-Line Data to be Released This Quarter JERUSALEM, April 5, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company's Phase IIb study of its oral [...]
JERUSALEM, March 29, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been granted by the Indian Patent Office. About Oramed [...]
Josh Hexter, Oramed's COO, spoke with Be Forum and about the company's recent China deal. www.beforum.org/the-bulletin/dancing-with-dragons
Josh Hexter, Oramed's COO, spoke with BioTuesdays.com about Oramed's progress and future advances. "Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and [...]